您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > BAY 41-8543
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
BAY 41-8543
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
BAY 41-8543图片
CAS NO:256498-66-5
包装与价格:
包装价格(元)
10mg电议
50mg电议

产品介绍

化学性质

Physical AppearanceA crystalline solid
StorageStore at -20°C
M.Wt420.4
Cas No.256498-66-5
FormulaC21H21FN8O
Solubility≤3mg/ml in dimethyl formamide
Chemical Name2-[1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(4-morpholinyl)-4,6-pyrimidinediamine
Canonical SMILESFC(C=CC=C1)=C1CN2N=C(C3=NC(N)=C(N4CCOCC4)C(N)=N3)C5=C2N=CC=C5
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。

资料参考

IC50: 0.09 μM human platelets

BAY 41-8543 is a soluble guanylate cyclase (sGC) stimulator.

Soluble guanylate cyclase (sGC) has been identified as the primary cellular receptor for nitric oxide (NO). NO can bind and activate a heme group in sGC, initiating the conversion of GTP to the second messenger cyclic GMP (cGMP).

In vitro: Previous study found that BAY 41-8543 could concentration-dependently stimulate the recombinant sGC up to 92-fold. Moreover, BAY 41-8543 and NO had synergistic effects over a wide range of concentrations. Similar results were shown that BAY 41-8543 stimulated the sGC directly and further made the enzyme more sensitive to its endogenous activator NO. In addition, BAY 41-8543 was found to be a potent relaxing agent of aortas, saphenous arteries, coronary arteries and veins with IC50-values in the nm range [1].

In vivo: In anaesthetized dogs, i.v. injections of BAY 41-8543 could cause a dose-dependent decrease in blood pressure and cardiac oxygen consumption as well as an increase in coronary blood flow and heart rate. In anaesthetized normotensive rats, BAY 41-8543 produced a dose-dependent and long-lasting blood pressure lowering effect. Moreover, a dose-dependent and long-lasting decrease in blood pressure was also observed in conscious spontaneously hypertensive rats with a threshold dose of 0.1 mg/kg p.o. [2].

Clinical trial: So far, no clinical study has been conducted.

References:
1.  Stasch, J.P.,Alonso-Alija, C.,Apeler, H., et al. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: In vitro studies. British Journal of Pharmacology 135, 333-343 (2002).
2.  Stasch, J.P.,Dembowsky, K.,Perzborn, E., et al. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. British Journal of Pharmacology 135, 344-355 (2002).